Compounds > N-(4Z-7Z-10Z-13Z-16Z-19Z)-docosahexaenoylethanolamine

N-(4Z-7Z-10Z-13Z-16Z-19Z)-docosahexaenoylethanolamine and Breast-Neoplasms

N-(4Z-7Z-10Z-13Z-16Z-19Z)-docosahexaenoylethanolamine has been researched along with Breast-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for N-(4Z-7Z-10Z-13Z-16Z-19Z)-docosahexaenoylethanolamine and Breast-Neoplasms

Article	Year
Modulating Tumor-Associated Macrophage Polarization by Synthetic and Natural PPARγ Ligands as a Potential Target in Breast Cancer. Cells, 2020, 01-10, Volume: 9, Issue:1 Activation of peroxisome proliferator-activated receptor gamma (PPARγ) elicits anti-proliferative effects on different tumor cells, including those derived from breast cancer. PPARγ is also expressed in several cells of the breast tumor microenvironment, among which tumor associated macrophages (TAMs) play a pivotal role in tumor progression and metastasis. We explored the ability of synthetic and natural PPARγ ligands to modulate TAM polarization. The ligands included rosiglitazone (BRL-49653), and two docosahexaenoic acid (DHA) conjugates, Topics: Breast Neoplasms; Cell Differentiation; Cell Line; Cell Polarity; Culture Media, Conditioned; Cytokines; Docosahexaenoic Acids; Ethanolamines; Female; Humans; Ligands; Molecular Targeted Therapy; Monocytes; PPAR gamma; Rosiglitazone; Tumor-Associated Macrophages	2020

Article

Year

Modulating Tumor-Associated Macrophage Polarization by Synthetic and Natural PPARγ Ligands as a Potential Target in Breast Cancer.

Cells, 2020, 01-10, Volume: 9, Issue:1

Activation of peroxisome proliferator-activated receptor gamma (PPARγ) elicits anti-proliferative effects on different tumor cells, including those derived from breast cancer. PPARγ is also expressed in several cells of the breast tumor microenvironment, among which tumor associated macrophages (TAMs) play a pivotal role in tumor progression and metastasis. We explored the ability of synthetic and natural PPARγ ligands to modulate TAM polarization. The ligands included rosiglitazone (BRL-49653), and two docosahexaenoic acid (DHA) conjugates,

Topics: Breast Neoplasms; Cell Differentiation; Cell Line; Cell Polarity; Culture Media, Conditioned; Cytokines; Docosahexaenoic Acids; Ethanolamines; Female; Humans; Ligands; Molecular Targeted Therapy; Monocytes; PPAR gamma; Rosiglitazone; Tumor-Associated Macrophages

2020